Ocugen (OCGN) said Thursday the Data and Safety Monitoring Board approved the continuation of its phase 1/2 trial for OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration.
Initial phase 2 data showed OCU410 is safe and well-tolerated, with no serious adverse events reported, the company said.
Ocugen said dosing will conclude in early 2025, Ocugen said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。